Circulating cell free DNA: a marker to predict the therapeutic response for biological DMARDs in rheumatoid arthritis
Authors:
- 10 December 2016
- journal article
- research article
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 20 (6) , 722-730
Abstract
Aim To evaluate the correlation between circulating cell‐free DNA (ccfDNA) in plasma and clinical disease activities in patients with rheumatoid arthritis (RA). Method The study group included 30 patients with RA who started biological disease‐modifying anti‐rheumatic drugs (DMARDs) therapy. The concentration of ccfDNA in plasma was measured by quantitative real‐time polymerase chain reaction at baseline to 24 weeks in every 4‐week period from 30 patients and 21 healthy individuals. We also evaluated the correlation between ccfDNA and the clinical activity or the therapeutic response for biological DMARDs, using the simplified disease activity index (SDAI), Disease Activity Score of 28 joints (erythrocyte sedimentation rate) and the European League Against Rheumatism (EULAR) response criteria. Synovial fluid samples of knee joints were collected from 13 patients with RA and 12 with osteoarthritis (OA) to measure ccfDNA. Result The concentration of ccfDNA in RA patients at baseline was higher than healthy controls (P = 0.016). After introducing biological DMARDs, ccfDNA was increased until 8 weeks from the baseline, and decreased after 12 weeks. The average of SDAI was improved in all patients enrolled. At 12 weeks after treatment, 15 patients were good responders to the EULAR response criteria, nine showed moderate response and six showed no response. ccfDNA in good responders was increased until 8 weeks, while those of moderate or no response were not (P = 0.042). In joint fluid of RA patients, ccfDNA was remarkably increased as compared to those from OA (P = 0.00011). Conclusion After introducing biological DMARDs, increase of ccfDNA at 8 weeks was associated with improvement of disease activities. Compared with biomarkers reported, ccfDNA is able to predict the early therapeutic effects of biological DMARDs in RA patients.Keywords
This publication has 33 references indexed in Scilit:
- Branched DNA-based Alu quantitative assay for cell-free plasma DNA levels in patients with sepsis or systemic inflammatory response syndromeJournal of Critical Care, 2016
- Circulating cell-free DNA in serum as a biomarker for diagnosis and prognostic prediction of colorectal cancerBritish Journal of Cancer, 2014
- Circulating cell-free DNA: A promising marker of regional lymphonode metastasis in breast cancer patientsCancer Biomarkers, 2012
- The Pathogenesis of Rheumatoid ArthritisNew England Journal of Medicine, 2011
- Rheumatoid arthritisThe Lancet, 2010
- Treating rheumatoid arthritis to target: recommendations of an international task forceAnnals of the Rheumatic Diseases, 2010
- Free fetal DNA in maternal plasma in anembryonic pregnancies: confirmation that the origin is the trophoblastPrenatal Diagnosis, 2007
- About the possible origin and mechanism of circulating DNAClinica Chimica Acta, 2001
- Quantitative Analysis of Fetal DNA in Maternal Plasma and Serum: Implications for Noninvasive Prenatal DiagnosisThe American Journal of Human Genetics, 1998
- Point mutations of the N‐ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemiaBritish Journal of Haematology, 1994